(MENAFN- ProactiveInvestors)South Africa based Goldplat (LON:GDP) was a stand-out as it gained as much as a third after revealing what it called significant progress in reducing a backlog of stockpiles and an easing of problems with a third party refiner. It was a less favourable day for Kodal Minerals (LON:KOD) which fell almost 40 per cent as it blamed low iron ore prices for what it described as 'mixed results'. Another of the week's biotech winners was Motif Bio (LON:MFTB) which advanced on the news of 'fast track' designation for its next-gen antibiotic Iclaprim. It means the drug will in all likelihood qualify for a priority review by US Food & Drug Administration (FDA). It also spelled good news for Amphion Innovations (LON:AMP) it owns just over a quarter of Motif as it was also a feature of AIM's risers column. African Potash's (LON:AFPO) supply contract totaliser moved up another two notches this week and naturally the summer's top performing share followed. Two separate deals into Zimbabwe and Malawi respectively will see a further 200000 tonnes of fertiliser sold. It comes after the company stuck a framework deal in August with Comesa (the Common Market for Eastern and Southern Africa). There was good funding news for Russia focussed Amur (LON:AMC) meanwhile as it pocketed 60% more than expected from its equity swap arrangement with Lanstead Capital. Petroceltic (LON:PCI) meanwhile shot up earlier in the week as Italy's ENI made the largest ever gas find in the Mediterranean offshore Egypt. It was seen as something of a boon for the Irish firm's exploration interests in the country where it currently produces just shy of 20000 barrels oil equivalent per day.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.